(i)no appreciable effects on unselected recurrent gliomas in talampanel monotherapy,(ii)well-tolerated without significant additional toxicity,(iii)superior survival and lower O(6)-methylguanine-DNA methyltransferase methylation of newly diagnosed glioblastoma patients receiving RT+TMZ and talampanel than only RT+TMZ treatment. The gene discussed is MGMT; the disease is central nervous system cancer.